Altanispac Labs

Altanispac Labs is a clinical-stage biopharmaceutical company dedicated to advancing differentiated therapies for dry eye and ocular surface diseases. The company is led by a team of scientific and business leaders with extensive experience in the development, regulatory approval, and commercialization of major ophthalmic products. In January 2026, Altanispac sublicensed PL9643, a Phase 3 melanocortin 1 receptor (MC1R) agonist, from Palatin Technologies for the treatment of dry eye disease. The company's approach focuses on restoring ocular surface homeostasis through patient-friendly products with potent biological activity. Altanispac aims to address significant unmet needs in ophthalmology by leveraging real-world clinical expertise and a data-driven development strategy.